Co-Diagnostics, Inc. Common Stock
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provide… Read more
Market Cap & Net Worth: Co-Diagnostics, Inc. Common Stock (CODX)
Co-Diagnostics, Inc. Common Stock (NASDAQ:CODX) has a market capitalization of $4.84 Million ($4.84 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31674 globally and #10427 in its home market, demonstrating a -47.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Co-Diagnostics, Inc. Common Stock's stock price $2.31 by its total outstanding shares 2095031 (2.10 Million).
Co-Diagnostics, Inc. Common Stock Market Cap History: 2017 to 2026
Co-Diagnostics, Inc. Common Stock's market capitalization history from 2017 to 2026. Data shows change from $5.53 Million to $4.84 Million (-10.07% CAGR).
Index Memberships
Co-Diagnostics, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.20 Trillion | 0.00% | #812 of 976 |
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.00% | #2583 of 3165 |
Weight: Co-Diagnostics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Co-Diagnostics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Co-Diagnostics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.40x
Co-Diagnostics, Inc. Common Stock's market cap is 0.40 times its annual revenue
0.67x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $5.53 Million | $7.66K | -$6.96 Million | 721.86x | N/A |
| 2018 | $3.12 Million | $39.91K | -$6.27 Million | 78.21x | N/A |
| 2019 | $1.88 Million | $214.97K | -$6.20 Million | 8.72x | N/A |
| 2020 | $19.48 Million | $74.55 Million | $42.48 Million | 0.26x | 0.46x |
| 2021 | $18.71 Million | $97.89 Million | $36.66 Million | 0.19x | 0.51x |
| 2022 | $5.28 Million | $34.22 Million | -$14.24 Million | 0.15x | N/A |
| 2023 | $2.79 Million | $6.81 Million | -$35.33 Million | 0.41x | N/A |
| 2024 | $1.57 Million | $3.92 Million | -$37.64 Million | 0.40x | N/A |
Competitor Companies of CODX by Market Capitalization
Companies near Co-Diagnostics, Inc. Common Stock in the global market cap rankings as of March 19, 2026.
Key companies related to Co-Diagnostics, Inc. Common Stock by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #84 globally with a market cap of $187.53 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #151 globally with a market cap of $119.88 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #170 globally with a market cap of $111.60 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #183 globally with a market cap of $105.38 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #84 | Abbott Laboratories | NYSE:ABT | $187.53 Billion | $108.49 |
| #151 | Stryker Corporation | NYSE:SYK | $119.88 Billion | $345.81 |
| #170 | Medtronic PLC | NYSE:MDT | $111.60 Billion | $87.21 |
| #183 | Boston Scientific Corp | NYSE:BSX | $105.38 Billion | $71.28 |
Co-Diagnostics, Inc. Common Stock Historical Marketcap From 2017 to 2026
Between 2017 and today, Co-Diagnostics, Inc. Common Stock's market cap moved from $5.53 Million to $ 4.84 Million, with a yearly change of -10.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.84 Million | +1270.11% |
| 2025 | $353.22K | -77.52% |
| 2024 | $1.57 Million | -43.61% |
| 2023 | $2.79 Million | -47.22% |
| 2022 | $5.28 Million | -71.78% |
| 2021 | $18.71 Million | -3.98% |
| 2020 | $19.48 Million | +938.87% |
| 2019 | $1.88 Million | -39.92% |
| 2018 | $3.12 Million | -43.56% |
| 2017 | $5.53 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Co-Diagnostics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.84 Million USD |
| MoneyControl | $4.84 Million USD |
| MarketWatch | $4.84 Million USD |
| marketcap.company | $4.84 Million USD |
| Reuters | $4.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.